Refine
Year of publication
Has Fulltext
- yes (62)
Is part of the Bibliography
- no (62)
Keywords
- LHC (7)
- ALICE (3)
- ALICE experiment (3)
- pp collisions (3)
- Beauty production (2)
- Diagnostik (2)
- Früherkennung (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Richtlinie (2)
- Single electrons (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 900 GeV (1)
- Active middle ear implants (1)
- Atomic and Molecular Physics (1)
- Auditory system (1)
- Biodiversity (1)
- Bone conduction devices (1)
- Breast cancer (1)
- CVID (1)
- Cancer detection and diagnosis (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Comparison with QCD (1)
- Consensus statement (1)
- Conservation biology (1)
- Electron-pion identification (1)
- Environmental impact (1)
- European Society for Immunodeficiencies (ESID) (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- German PID-NET registry (1)
- HBT (1)
- Hadron production (1)
- Health policy (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Histology (1)
- Hsp70 (1)
- Human genetics (1)
- IHC (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Ionisation energy loss (1)
- Jets (1)
- Mid-rapidity (1)
- Mixed hearing loss (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Myeloid Neoplasia (1)
- NK cells (1)
- Neural network (1)
- Nuclear modification factor (1)
- Oncology (1)
- Ovarian cancer (1)
- PID prevalence (1)
- PYTHIA (1)
- Pb–Pb (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- Rehabilitation (1)
- SCCHN (1)
- Single muons (1)
- Surgery (1)
- TR (1)
- Technical data (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- azacitidine (1)
- cardiocerebral resuscitation (1)
- cardiopulmonary resuscitation (1)
- child (1)
- dE/dx (1)
- follow-up (1)
- hematopoietic stem cell transplantation (1)
- juvenile myelomonocytic leukemia (1)
- leukemia (1)
- mutation (1)
- noise intervention measures (1)
- nursery schools (1)
- occupational health (1)
- pharmacokinetics (1)
- primary immunodeficiency (PID) (1)
- prognostic biomarker (1)
- registry for primary immunodeficiency (1)
- retrospective trial (1)
- sound analyses (1)
- spectra (1)
- √sN N = 2.76 TeV (1)
Institute
Untersuchungen über die Ernährung der Vögel sind ein traditionelles Arbeitsgebiet der Ornithologie (EMMRICH 1973). Spezielle Arbeiten zur Bedeutung von Spinnentieren (Arachnida) und ihrem Vorkommen in der Vogelnahrung sind aber selten. Gerade Angaben über Weberknechte verbergen sich oft unter dem Namen Arachnida (z. B. PFEIFER & KEJL 1958), selten ist die Ordnung Opiliones konkret angeführt (z. B. DORNBUSCH 1981, EMMRICH 1973, KRISTIN 1992). BURES (1986) erwähnt immerhin die gefundenen Gattungen. Das Spektrum der gefundenen Weberknechtarten geben nur wenige Autoren an (z. B. SACHER & DORNBUSCH 1990). Im Zuge eines Forschungsprojekts zur Ernährung von Vogelnestlingen in Wäldern und Hecken (z. B. KRISTIN 1992, 1993) konnten auch Daten über Weberknechte in der Nestlingsnahrung gesammelt werden. Sie sollen im Folgenden kurz dargestellt werden.
Der Fang von Vögeln zu wissenschaftlichen Zwecken in den Tropen und Subtropen stellt eine Herausforderung für Ornithologen dar. Probleme aufgrund rechtlicher sowie sozioökonomischer und soziokultureller Rahmenbedingungen lassen sich oft durch eine intensive Vorbereitung und Kooperationen mit lokalen Partnern vermeiden oder reduzieren. Beim eigentlichen Fang sind logistische Herausforderungen wie die Materialbeschaffung vor Ort, aber auch die Ökologie einiger überwiegend tropischer Vogelgruppen zu berücksichtigen. Hier wie auch bei der Probennahme und -lagerung beeinflussen die herrschenden Umweltbedingungen die Arbeit, insbesondere extreme Witterung. Problemlösungenlassen sich jedoch teilweise nur schwer verallgemeinern. Wir unterstreichen die Bedeutung lokaler und regionaler Besonderheiten anhand zahlreicher Beispiele aufgrund eigener Erfahrungen.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
(2021)
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the disorder prior to HSCT are needed. We conducted a phase 2, multicenter, open-label study to evaluate the safety and antileukemic activity of azacitidine monotherapy prior to HSCT in newly diagnosed JMML patients. Eighteen patients enrolled from September 2015 to November 2017 were treated with azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle. The primary end point was the number of patients with clinical complete remission (cCR) or clinical partial remission (cPR) after 3 cycles of therapy. Pharmacokinetics, genome-wide DNA-methylation levels, and variant allele frequencies of leukemia-specific index mutations were also analyzed. Sixteen patients completed 3 cycles and 5 patients completed 6 cycles. After 3 cycles, 11 patients (61%) were in cPR and 7 (39%) had progressive disease. Six of 16 patients (38%) who needed platelet transfusions were transfusion-free after 3 cycles. All 7 patients with intermediate- or low-methylation signatures in genome-wide DNA-methylation studies achieved cPR. Seventeen patients received HSCT; 14 (82%) were leukemia-free at a median follow-up of 23.8 months (range, 7.0-39.3 months) after HSCT. Azacitidine was well tolerated and plasma concentration-–time profiles were similar to observed profiles in adults. In conclusion, azacitidine monotherapy is a suitable option for children with newly diagnosed JMML. Although long-term safety and efficacy remain to be fully elucidated in this population, these data demonstrate that azacitidine provides valuable clinical benefit to JMML patients prior to HSCT. This trial was registered at www.clinicaltrials.gov as #NCT02447666.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.
Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.
Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.
Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.
Buchbesprechungen
(2014)
Es werden folgende Publikation rezensiert: Baumbach & Pfützenreuter: Steppenlebensräume Europas, Beil et al.: Die Sand-Silberscharte in Hessen, Bönsel et al.: Naturschätze in Gießen, Bönsel et al.: Von Venuskamm, Finkensame und Hasenohr, Bönsel et al.: Die Pflanzenwelt im Westerwald, Hodvina: Die Pflanzenaquarelle des Emil Pfeiffer, Jenrich et al.: Das Rote Moor, Lange: Blütenzauber, Magistrat der Stadt Offenbach am Main: Lebensräume und Artenvielfalt in Offenbach, Schmidt & Meyer: Hessische Naturwaldreservate im Portrait: Kinzigaue.
Background: Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated.
Methods: Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C, RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history.
Results: In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients ≥60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2% (29.1%) and 10.2% (14.8%), respectively. Testing only for BRCA1/2 would miss in our series more than 5% of the patients with a deleterious variant in established risk genes.
Conclusions: 26.4% of all patients harbor at least one deleterious variant in established risk genes. The threshold of 10% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing. Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to BRCA1/2 seems to be not sufficient.
Background: Panic disorder is common (5% prevalence) and females are twice as likely to be affected as males. The heritable component of panic disorder is estimated at 48%. Glutamic acid dehydrogenase GAD1, the key enzyme for the synthesis of the inhibitory and anxiolytic neurotransmitter GABA, is supposed to influence various mental disorders, including mood and anxiety disorders. In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females.
Methodology/Principal Findings: Nineteen single nucleotide polymorphisms (SNPs) tagging the common variation in GAD1 were genotyped in two independent gender and age matched case-control samples (discovery sample n = 478; replication sample n = 584). Thirteen SNPs passed quality control and were examined for gender-specific enrichment of risk alleles associated with panic disorder by using logistic regression including a genotype×gender interaction term. The latter was found to be nominally significant for four SNPs (rs1978340, rs3762555, rs3749034, rs2241165) in the discovery sample; of note, the respective minor/risk alleles were associated with panic disorder only in females. These findings were not confirmed in the replication sample; however, the genotype×gender interaction of rs3749034 remained significant in the combined sample. Furthermore, this polymorphism showed a nominally significant association with the Agoraphobic Cognitions Questionnaire sum score.
Conclusions/Significance: The present study represents the first systematic evaluation of gender-specific enrichment of risk alleles of the common SNP variation in the panic disorder candidate gene GAD1. Our tentative results provide a possible explanation for the higher susceptibility of females to panic disorder.
Es werden folgende Publikationen rezensiert: Chytrý: Vegetation of the Czech Republic 1, Chytrý: Vegetation of the Czech Republic 2, Chytrý: Vegetation of the Czech Republic 3, Eger & Kesper: Flechten zwischen Eder und Diemel, Gerster: Kräuterwissen, Meyer: Pflanzen Nordhessens, Mollenhauer: Gregor Kraus, Seibold: Schmeil-Fitschen, Suck & Bushart: Karte der Potentiellen Natürlichen Vegetation Deutschlands, Süß & al.: Ried und Sand.